Dishman Carbogen Amcis Limited (NSE:DCAL)

India flag India · Delayed Price · Currency is INR
244.65
-9.60 (-3.78%)
Aug 1, 2025, 3:30 PM IST
-3.78%
Market Cap38.36B
Revenue (ttm)27.12B
Net Income (ttm)32.40M
Shares Out156.78M
EPS (ttm)0.21
PE Ratio1,183.86
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume63,666
Average Volume91,996
Open256.50
Previous Close254.25
Day's Range242.40 - 256.50
52-Week Range161.21 - 307.98
Beta0.17
RSI43.28
Earnings DateAug 8, 2025

About Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1983
Employees 1,132
Stock Exchange National Stock Exchange of India
Ticker Symbol DCAL
Full Company Profile

Financial Performance

Financial Statements

News

Dishman Carbogen clears US FDA inspection at Naroda facility with no observations

Dishman Carbogen Amcis Ltd has announced the successful completion of a scheduled US FDA inspection at its Naroda facility in Ahmedabad. The inspection, which was planned from June 9 to June 13, 2025,...

7 weeks ago - Business Upturn

Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement

Shares of Dishman Carbogen Amcis Ltd. could see increased investor interest after its Swiss subsidiary, CARBOGEN AMCIS AG, announced a strategic co-investment exceeding CHF 25 million with a key Japan...

2 months ago - Business Upturn

Dishman Carbogen Amcis shares surge over 11% as company swings to profit in Q4, EBITDA margin doubles

Shares of Dishman Carbogen Amcis Ltd jumped 11.12% to ₹244.50 on Thursday after the company reported a turnaround in its financial performance for the March quarter (Q4 FY25). The stock was among the ...

2 months ago - Business Upturn

Dishman Carbogen shares surge 5% after arm gets drug manufacturing licence In China

Dishman Carbogen Amcis Ltd. witnessed a 5% jump in its share price after announcing a significant regulatory milestone. Its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has secured a D...

4 months ago - Business Upturn

Dishman Carbogen Amcis subsidiary receives drug manufacturing license in China

Dishman Carbogen Amcis Ltd. has announced that its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a Drug Manufacturing License from the National Medical Products Administrat...

4 months ago - Business Upturn

Dishman Carbogen Amcis shares jump nearly 2% after board approves Rs 50 crore debenture issuance

Shares of Dishman Carbogen Amcis Ltd gained 1.90% to ₹210.22 on Wednesday after the company’s board approved the issuance of rated, listed, senior, secured, redeemable, taxable non-convertible debentu...

5 months ago - Business Upturn

Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript

Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript

6 months ago - GuruFocus

Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility

CARBOGEN AMCIS AG, a subsidiary of Dishman Carbogen Amcis Limited, has announced the successful completion of a Swissmedic inspection at its Vionnaz facility in Switzerland. This achievement reaffirms...

7 months ago - Business Upturn